|
Mr. Watumull has more than twenty years experience as a biotech industry executive, analyst, and investment banker. He is co-founder of Cardax Pharmaceuticals. Previously, during his tenure as CEO of Hawaii Biotech, Inc., the company raised more than $25 million in investor financing and was awarded an additional $30 million in federal grand and contract funding. Prior to the spin-out of Cardax Pharmaceuticals from Hawaii Biotech, $7 million of the investor funding was directly applied to anti-inflammatory programs now contained in Cardax Pharmaceuticals. An additional $8 million of the investor funding was included in the Cardax Pharmaceuticals spin-out and is being used as starting working capital. Prior to Hawaii Biotech Mr. Watumull worked at Paine Webber as a biotech money manager and investment executive, First Honolulu Securities as a biotech money manager, biotech industry analyst, and investment banker, and Aquasearch as Executive Vice president, Finance and Strategic Direction. His clients during his analyst career included the Wisconsin Investment Board, the world's largest biotech investor at that time. While at Paine Webber, Mr. Watumull helped obtain financing for Amgen, Genentech, and Centocor. Mr. Watumull is also incoming Chairman of the Hawaii Science and Technology Council, the industry's trade association in Hawaii. He was also name one of Hawaii's "Ten Who Made a Difference" by the Honolulu Star-Bulletin for 1994. Mr. Watumull graduated from Punahou School and attended Claremont Men's College (now Claremont McKenna), majoring in mathematics, and has lectured at the University of Hawaii business school. | 